Literature DB >> 3422645

Quantification of immunoglobulin on electrophoretic immunoblot strips as a tool for human immunodeficiency virus serodiagnosis.

J Blomberg1, P J Klasse.   

Abstract

Electrophoretic immunoblotting (EIB [Western blotting]), the main method for verification of human immunodeficiency virus (HIV) seropositivity, needs thorough characterization and standardization. We explored the possibilities of quantifying immunoglobulin G (IgG) bound to EIB strips both by densitometry of the peroxidase-stained bands and by measurement of radioactivity with labeled anti-HIV IgG. The radioactivity method is inherently more exact but was more cumbersome. However, despite saturation phenomena at high IgG densities, the densitometric method was more convenient and yielded reproducible estimates of the amount of bound IgG. We found it useful primarily for documentation of changes in the relative abundance of antibodies to different HIV proteins from individual patients over time. To explore the potential usefulness of the method, we studied a small set of HIV-seropositive persons. The average p24/gp41 color yield ratios and standard deviations in 3 persons with recent seroconversion, 15 healthy subjects, and 6 diseased HIV-seropositive persons were 6.6 +/- 0.9, 2.3 +/- 1.9, and 1.3 +/- 0.5, respectively. These data are in accord with previous qualitative or semiquantitative observations but are too limited for any conclusions regarding the use of quantitative EIB for prognostic use with individual patients. Quantitative EIB is a valuable tool for comparative methodological studies and for research on the protective role of anti-HIV antibodies in acquired immunodeficiency syndrome pathogenesis. Its possible use in prognostication for individual patients must be evaluated in long-term studies.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3422645      PMCID: PMC266207          DOI: 10.1128/jcm.26.1.111-115.1988

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  26 in total

1.  Seroepidemiology of human immunodeficiency virus in Africa.

Authors:  I Wendler; J Schneider; B Gras; A F Fleming; G Hunsmann; H Schmitz
Journal:  Br Med J (Clin Res Ed)       Date:  1986-09-27

2.  Serological characterization of HTLV-III infection in AIDS and related disorders.

Authors:  J E Groopman; F W Chen; J A Hope; J M Andrews; R L Swift; C V Benton; J L Sullivan; P A Volberding; D P Sites; S Landesman
Journal:  J Infect Dis       Date:  1986-04       Impact factor: 5.226

3.  False-positive Western blot tests for antibodies to HTLV-III.

Authors:  D S Burke; R R Redfield
Journal:  JAMA       Date:  1986-07-18       Impact factor: 56.272

4.  Reflective densitometry of Western blots to quantitate the developmentally regulated accumulation of myosin light chain 3.

Authors:  P A Merrifield; I R Konigsberg
Journal:  Biochem Biophys Res Commun       Date:  1986-03-28       Impact factor: 3.575

5.  Blood donor sera with false-positive Western blot reactions to human immunodeficiency virus.

Authors:  G Biberfeld; U Bredberg-Rådén; B Böttiger; P O Putkonen; J Blomberg; P Juto; G Wadell
Journal:  Lancet       Date:  1986-08-02       Impact factor: 79.321

6.  Anti-STLV-IIImac reactivity in HIV seropositive individuals in Sweden.

Authors:  J Blomberg; P J Klasse; L Kjelle'n; M D Daniel
Journal:  Lancet       Date:  1986-08-09       Impact factor: 79.321

7.  Blood donations reactive for HIV in Western blot, but non-infective in culture and recipients of blood.

Authors:  C L van der Poel; H W Reesink; T Tersmette; P N Lelie; H Huisman; F Miedema
Journal:  Lancet       Date:  1986-09-27       Impact factor: 79.321

8.  Distinct IgG recognition patterns during progression of subclinical and clinical infection with lymphadenopathy associated virus/human T lymphotropic virus.

Authors:  J M Lange; R A Coutinho; W J Krone; L F Verdonck; S A Danner; J van der Noordaa; J Goudsmit
Journal:  Br Med J (Clin Res Ed)       Date:  1986-01-25

9.  Quantification of specific antibody response to Cryptosporidium antigens by laser densitometry.

Authors:  B L Ungar; T E Nash
Journal:  Infect Immun       Date:  1986-07       Impact factor: 3.441

10.  Quantitative Western blot assay for measurement of the murine acute phase reactant, serum amyloid P component.

Authors:  D E Griswold; L Hillegass; L Antell; A Shatzman; N Hanna
Journal:  J Immunol Methods       Date:  1986-07-24       Impact factor: 2.303

View more
  5 in total

1.  Quantitative western immunoblotting analysis in survey of human immunodeficiency virus-seropositive patients.

Authors:  D G Schiavini; J M Puel; S A Averous; J A Bazex
Journal:  J Clin Microbiol       Date:  1989-09       Impact factor: 5.948

2.  Monitoring human immunodeficiency virus type 1-infected patients by ratio of antibodies to gp41 and p24.

Authors:  G Schmidt; K Amiraian; H Frey; J Wethers; R W Stevens; D S Berns
Journal:  J Clin Microbiol       Date:  1989-05       Impact factor: 5.948

3.  Quantitation of antibody reactivity to human immunodeficiency virus (type 1) proteins and glycoproteins on Western immunoblots by reflectance densitometry.

Authors:  C T Hardy; T A Damrow; G E Kenny
Journal:  J Clin Microbiol       Date:  1990-11       Impact factor: 5.948

4.  Specificities and sensitivities of three systems for determination of antibodies to human immunodeficiency virus by electrophoretic immunoblotting.

Authors:  J Blomberg; P J Klasse
Journal:  J Clin Microbiol       Date:  1988-01       Impact factor: 5.948

5.  Presence of antibodies to a putatively immunosuppressive part of human immunodeficiency virus (HIV) envelope glycoprotein gp41 is strongly associated with health among HIV-positive subjects.

Authors:  P J Klasse; R Pipkorn; J Blomberg
Journal:  Proc Natl Acad Sci U S A       Date:  1988-07       Impact factor: 11.205

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.